KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat Aug 18, 2015 09:00AM
KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update Aug 6, 2015 04:05PM
KYTHERA Biopharmaceuticals Announces Health Canada Authorization of BELKYRA(TM), a Submental Contouring Injectable Drug(i) Jul 27, 2015 09:00AM
KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM) -- First FDA-Approved Injectable Treatment for “Double Chin” -- Through KYBELLA(TM) Trained Physicians Jun 19, 2015 09:00AM
Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug Apr 29, 2015 03:58PM


Apr 29, 2015 03:58PM Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug
Mar 9, 2015 12:45PM KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Unanimously (17-0) Recommends to Approve ATX-101 (deoxycholic acid) Injection to Improve the Appearance of Moderate to Severe Submental Full
Mar 9, 2015 12:45PM KYTHERA Biopharmaceuticals Announces FDA Advisory Committee Unanimously (17-0) Recommends to Approve ATX-101 (deoxycholic acid) Injection to Improve the Appearance of Moderate to Severe Submental Full
Mar 2, 2015 04:56PM KYTHERA Biopharmaceuticals Announces 2014 Operating Results